SHSE:688163 (China)
Â
Class A
Â¥
28.42
-0.98 (-3.33%)
Jul 29
Business Description
Shanghai Serum Bio Technology Co Ltd
ISIN : CNE1000059X8
Share Class Description:
SHSE:688163: Class ATotal Employee Number:
330Compare
Compare
Traded in other countries / regions
688163.China Index Membership
SSE Composite Index IPO Date
2022-03-11Description
Shanghai Serum Bio Technology Co Ltd is engaged in the research, development, production and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 154.69 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | 0.08 | |||||
Interest Coverage | 295.02 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 48.19 | |||||
Beneish M-Score | -2.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.1 | |||||
3-Year EBITDA Growth Rate | -4.1 | |||||
3-Year EPS without NRI Growth Rate | -3.9 | |||||
3-Year FCF Growth Rate | -71.9 | |||||
3-Year Book Growth Rate | -0.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.46 | |||||
9-Day RSI | 29.13 | |||||
14-Day RSI | 33.26 | |||||
3-1 Month Momentum % | 25.19 | |||||
6-1 Month Momentum % | 76.63 | |||||
12-1 Month Momentum % | 81.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 26.4 | |||||
Quick Ratio | 25.03 | |||||
Cash Ratio | 22.65 | |||||
Days Inventory | 362.13 | |||||
Days Sales Outstanding | 110.13 | |||||
Days Payable | 81.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.29 | |||||
Dividend Payout Ratio | 0.67 | |||||
3-Year Dividend Growth Rate | -29.2 | |||||
Forward Dividend Yield % | 1.29 | |||||
5-Year Yield-on-Cost % | 1.28 | |||||
Shareholder Yield % | 1.34 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.8 | |||||
Operating Margin % | 26.42 | |||||
Net Margin % | 24.58 | |||||
EBITDA Margin % | 30.67 | |||||
FCF Margin % | -4.47 | |||||
OCF Margin % | 35.26 | |||||
ROE % | 4.37 | |||||
ROA % | 4.24 | |||||
ROIC % | 12.28 | |||||
3-Year ROIIC % | -7.16 | |||||
ROC (Joel Greenblatt) % | 21.58 | |||||
ROCE % | 5.43 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 61.78 | |||||
PE Ratio without NRI | 59.58 | |||||
Shiller PE Ratio | 43.06 | |||||
Price-to-Owner-Earnings | 168.18 | |||||
PS Ratio | 13.08 | |||||
PB Ratio | 2.76 | |||||
Price-to-Tangible-Book | 2.82 | |||||
Price-to-Operating-Cash-Flow | 50.78 | |||||
EV-to-EBIT | 40.4 | |||||
EV-to-EBITDA | 40.4 | |||||
EV-to-Revenue | 12.39 | |||||
EV-to-FCF | -277.55 | |||||
Price-to-GF-Value | 1.14 | |||||
Price-to-Projected-FCF | 1.63 | |||||
Price-to-Graham-Number | 2.73 | |||||
| Price-to-Net-Current-Asset-Value | 3.62 | |||||
| Price-to-Net-Cash | 4.25 | |||||
Earnings Yield (Greenblatt) % | 2.48 | |||||
FCF Yield % | -0.29 | |||||
Forward Rate of Return (Yacktman) % | -21.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Serum Bio Technology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 197.678 | ||
| EPS (TTM) (Â¥) | 0.46 | ||
| Beta | 0.9398 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 1.49 | ||
| Volatility % | 49.91 | ||
| 14-Day RSI | 33.26 | ||
| 14-Day ATR (Â¥) | 3.24823 | ||
| 20-Day SMA (Â¥) | 37.932 | ||
| 12-1 Month Momentum % | 81.34 | ||
| 52-Week Range (Â¥) | 21.2 - 52.88 | ||
| Shares Outstanding (Mil) | 108.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Serum Bio Technology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Serum Bio Technology Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.260000 Cash Dividend | 2026-05-29 | 36.86 (+1.46%) | ||
| CNY 0.120000 Cash Dividend | 2025-09-26 | 23.10 (-0.99%) | ||
| CNY 0.200000 Cash Dividend | 2025-06-05 | 19.42 (-2.31%) | ||
| CNY 0.120000 Cash Dividend | 2024-09-12 | 15.40 (+0.00%) |
Show
Entries
Shanghai Serum Bio Technology Co Ltd Frequently Asked Questions
What is Shanghai Serum Bio Technology Co Ltd(SHSE:688163)'s stock price today?
The current price of SHSE:688163 is ¥28.42. The 52 week high of SHSE:688163 is ¥52.88 and 52 week low is ¥21.20.
When is next earnings date of Shanghai Serum Bio Technology Co Ltd(SHSE:688163)?
The next earnings date of Shanghai Serum Bio Technology Co Ltd(SHSE:688163) is .
Does Shanghai Serum Bio Technology Co Ltd(SHSE:688163) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Serum Bio Technology Co Ltd(SHSE:688163) is 1.29% (As of Today), Highest Dividend Payout Ratio of Shanghai Serum Bio Technology Co Ltd(SHSE:688163) was 3.41. The lowest was 0.67. And the median was 1.64. The  Forward Dividend Yield % of Shanghai Serum Bio Technology Co Ltd(SHSE:688163) is 1.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shanghai Serum Bio Technology Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers